<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Zarifyan, Alla</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Saver, Jeffrey L.</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Solitaire Stent Reduced Disability in Stroke Patients in the SWIFT PRIME Trial</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2015-03-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">15-16</style></pages><abstract><style  face="normal" font="default" size="100%">The SWIFT PRIME study demonstrated that the Solitaire stent was safe and effective at reducing poststroke disability in patients with acute ischemic stroke. Functional independence (mRS of 0 to 2) at 90 days was achieved in 60.2% of patients in the Solitaire plus IV tPA group vs 35.5% in the IV tPA group (P &lt; .0008).</style></abstract><number><style face="normal" font="default" size="100%">2</style></number><volume><style face="normal" font="default" size="100%">15</style></volume></record></records></xml>